Cephalosporin Drugs Market Size Worth US$ 19,073.1 Million with CAGR of 3.8% by 2026, Owing to Increasing R&D Activities Related to Cephalosporin Drugs
Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
According to Global Cephalosporin Drugs Market Report, by Generation (First-generation Cephalosporin, Second-generation Cephalosporin, Third-generation Cephalosporin, Fourth-generation Cephalosporin, and Fifth-generation Cephalosporin), By Type (Branded Cephalosporin Drugs and Generic Cephalosporin Drugs), by Formulation (Oral ( Tablets, Capsules, and Liquid) and Injection), by Indication (Respiratory Tract Infection, Skin Infection, Ear Infection, Bacterial Infection, Urinary Tract Infection, Sexually Transmitted Infection, Sinus Infection, Surgical Prophylaxis, and Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), published by Coherent Market Insights, the global cephalosporin drugs market was valued at US$ 14,240.0 million in 2018, and is projected to exhibit a CAGR of 3.8% over the forecast period (2019 – 2026).
Request FREE Sample
Increasing number of clinical trials for R&D of cephalosporin drugs is expected to propel growth of the global cephalosporin drugs market over the forecast period. For instance, in April 2017, Basilea Pharmaceutica Ltd. announced that it has reached agreement with the U.S. FDA on Special Protocol Assessments (SPAs) for its two planned phase III clinical studies of Basilea’s antibiotic ceftobiprole (fifth generation). The two studies will evaluate ceftobiprole for the treatment of Staphylococcus aureus bacteremia (bloodstream infections) and acute bacterial skin and skin structure infections.
Moreover, increasing funding for R&D in antibiotic resistance is also expected to boost growth of the global cephalosporin drugs market. For instance, in September 2018, National Institutes of Health (NIH) granted US$ 9.4 million for establishing the Center for Biomedical Research Excellence (COBRE) to address the worldwide threat of drug-resistant pathogens to The Miriam Hospital in Rhode Island, U.S.
To know the latest trends and insights related to global cephalosporin drugs market PRESS RELEASE, click the link below: https://www.coherentmarketinsights.com/press-release/cephalosporin-drugs-market-to-surpass-us-190731-million-by-2026-1729
Among generations, the third-generation cephalosporin segment is expected to account for major revenue share in 2026 in the global cephalosporin drugs market, owing to increasing launch of third-generation cephalosporin drugs. For instance, in March 2017, Pfizer Inc. launched the antibiotic Zavicefta (third-generation cephalosporin) in the U.K. and Germany for the treatment of aerobic gram-negative infections caused by resistant bacteria.
Key players in the market are focused on launching new products to expand their product portfolio. For instance, in April 2018, Basilea Pharmaceutica Ltd. announced that its partner Avir Pharma Inc. launched Basilea’s hospital antibiotic Zevtera (ceftobiprole) in Canada. Furthermore, in May 2018, Basilea Pharmaceutica Ltd. announced that its partner Hikma Pharmaceuticals LLC launched Basilea’s hospital antibiotic Zevtera (ceftobiprole) in Saudi Arabia.
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/2893
Key Takeaways
- The global cephalosporin drugs market is expected to witness a CAGR of 3.8% during the forecast period (2019–2026)
- Increasing number of clinical trials for R&D of cephalosporin drugs is expected to propel growth of the global cephalosporin drugs market over the forecast period
- Major players operating in the global cephalosporin drugs market include Merck & Co. Inc., GlaxoSmithKline plc., Pfizer Inc., Allergan plc., Abbott Laboratories, Basilea Pharmaceutica Ltd., Sanofi S.A., F. Hoffmann-La Roche AG, Lupin Limited, Teva Pharmaceutical Industries Ltd., and B. Braun Melsungen AG
Other Related Reports:
About Us:Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.
Editor Details
-
Company:
- CDN Newswire
